From DCAT Value Chain Insights (VCI)
The US Food and Drug Administration (FDA) has issued draft guidance, Quality Attribute Considerations for Chewable Tablets, to provide manufacturers of chewable tablets for human use FDA's Center for Drug Evaluation and Research’s (CDER) current thinking on the critical quality attributes that should be assessed during the development of these drug products.
The draft guidance also provides recommendations about submitting developmental, manufacturing, and labeling information for chewable tablets that must be approved by CDER before they can be distributed. The
recommendations in the guidance apply mainly to new drug applications, abbreviated new drug applications, and certain chemistry, manufacturing, and controls supplements to these applications. Some of the recommendations about the submission of developmental information may also apply to investigational new drug applications. The recommendations about assessing critical quality attributes apply to all chewable tablets for human use, including non-application products.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription